By physician referral or invitation only

MK-8527 as HIV-1 PrEP

To test the safety of the trial drug, MK-8527 compared to emtricitabine/tenofovir (FTC/TDF) and to see how well MK-8527 works to reduce the chance of getting HIV-1 infection compared to FTC/TDF.

Age & Gender

16 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Lina Rosengren-Hovee
Institute for Global Health and Infectious Diseases

Study Type

Clinical or Medical
Interventional

Study Topics

Healthy Volunteer or General Population
HIV/AIDS

IRB Number

25-1677

ClinicalTrials.gov

NCT07044297

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.